000			02123nam a2200397 c4500
999			_c12382 _d12382
001			12382
003			ES-MaUEC
005			20211214040353.0
006			a||||fo|||| 00| 0
007			cr nn nnnanaaa
008			190626s2019 gw a o |||| 0|eng d
020			_a9783030740283
024	7		_a10.1007/978-3-030-74028-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280 _b.L86 2021 EB
245	0	0	_aLung Cancer: _b New Understandings and Therapies _cedited by Anne C. Chiang, Roy S. Herbst
250			_a1st ed. 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (VI, 264 páginas) _b1 b/w illustrations, 16 illustrations in colour
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aCurrent Cancer Research _x2199-2584
490	0		_aMedicine (Springer-11650)
520	3		_aLung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
988			_aSegundosemestre_2021_Medicine
650		7	_aPulmones _xCáncer _2embne _9168954
700			_aChiang, Anne C. _9517736
700			_aHerbst, Roy S. _9517737
710	2		_aSpringerLink (Online service) _9106996
776	0	8	_iPrinted edition: _z978-3-030-74030-6
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-74028-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db _feng _ggw _h0 _zSI